Re-confirmation of information may be requested periodically to ensure accuracy of data and compliance with terms. This offer is valid in the United States and may be redeemed at participating retail pharmacies.
Absent a change in Massachusetts law, effective July 1, , the Savings Card will no longer be valid for residents of Massachusetts. Void where taxed, restricted, or prohibited by law. This offer is not transferable and is limited to one offer per person.
Not valid if reproduced. Cash Discount Cards and other non-insurance plans are not valid as primary insurance under this offer. If the patient is eligible for drug benefits under any such program, the patient cannot use this offer. This Savings Card cannot be combined with any coupon, certificate, voucher, or similar offer. Patient is responsible for complying with any insurance carrier co-payment disclosure requirements, including disclosing any savings received from this program.
It is illegal to or offer to sell, purchase, or trade this offer. This program is managed by ConnectiveRx on behalf of Novo Nordisk. NovoSeven has been studied in patients with haemophilia and in patients with factor VII deficiency. The main measure of effectiveness was the number of bleeding episodes that were controlled effectively.
Side effects with NovoSeven are not common. However the following side effects may affect between 1 and 10 patients in 1, venous thromboembolic events problems caused by blood clots in the veins , rash, pruritus itching , urticaria hives , fever and reduced effectiveness of treatment. For the full list of side effects of NovoSeven, see the package leaflet. NovoSeven must not be used in people who are hypersensitive allergic to eptacog alfa, to mouse, hamster or cow proteins, or to any of the other ingredients.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of NovoSeven have been included in the summary of product characteristics and the package leaflet.
As for all medicines, data on the use of NovoSeven are continuously monitored. Side effects reported with NovoSeven are carefully evaluated and any necessary action taken to protect patients. NovoSeven received a marketing authorisation valid throughout the EU on 23 February More detail is available in the summary of product characteristics.
NovoSeven is indicated for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:. Please do not include any personal data , such as your name or contact details. Skip to main content. Veterinary regulatory Overview Research and development Marketing authorisation Post-authorisation.
NovoSeven RSS. You may find that their experiences are similar to yours. Hear their stories. Connect With an HCL. Learn About Options. Novo Nordisk Information and Resources.
0コメント